International Journal of Pharma Research and Technology

An Overview on Pluripotent Stem Cell Genetic Transfer

Patil M.S.[1*], Shinde k.A.[2]
MET Institute of pharmacy Adagaon, Nashik 422003
KSS College of Pharmacy Shikrapur 412208
manasvipatil2016@gmail.com

Abstract

In order to treat diseases like lymphoma, leukaemia, immune-deficiency disorders, congenital metabolic abnormalities, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes, more than 25,000 hematopoietic stem cell transplants (HSCTs) are carried out annually. Patients undergo extensive myeloablative chemoradiotherapy prior to transplantation, followed by stem cell "rescue." The patient's own hematopoietic stem cells, which are removed before to transplantation and reinfused following myeloablation, are employed in autologous HSCT. Human leukocyte antigen (HLA)-matched stem cells from a donor are used in allogeneic HSCT. The likelihood of surviving an allogeneic transplant depends on the compatibility of the donor and recipient, the graft-versus-host reaction, and the emergence of a graft-versus-leukemia effect. The biology of stem cells, the clinical effectiveness of HSCT, transplantation techniques, and potential drawbacks are all covered in this article.

Keywords: Hematopoietic Stem Cell Transplantation, Complications

Introduction

The term "stem cells" refers to a population of undifferentiated cells that can self-renew indefinitely and give rise to a functional offspring of highly specialized cells. They are present throughout the body. Depending on where they are located or what tissue compartment they are in, stem cells have distinct proliferative characteristics and roles. All mature blood lineages can be formed from hematopoietic stem cells (HSCs), which have the capacity to self-renew and differentiate. 1,2 Hematopoiesis is a continuous developmental process in which HSCs make specific cell fate decisions, producing the various blood lineages.[3]

A complicated regulatory network that is still poorly understood is necessary for the production and maintenance of the proper numbers and types of mature cells. Hematopoietic cell differentiation and growth are controlled by stromal interactions with soluble and cell-bound cytokines.[4] The earliest HSCs also express the cell surface antigen CD34, kinase domain receptor (KDR [flk-1]), vascular endothelial growth factor, and the positive hemopoietic development regulators, c-kit and flt-3, which can be employed to expand HSCs ex vivo.[5]

HSCs for transplantation can be obtained from peripheral blood or bone marrow (BM). Hematopoietic restoration following BM ablation is dependent on intravenous injected stem cells migrating and "homing" to the hematopoietic milieu in the recipient's BM niches6. The multiple steps of HSC "homing" involve the successive activation of adhesion molecules.[7] The chemoattractant for monocyte, lymphocyte, and CD34+ cell homing was

 https://doi.org/10.5281/zenodo.7461148

first identified as stromal cell-derived factor-1 (SDF-1). SDF-1 and vascular ligands, such as intercellular adhesion molecule-1 and vascular cellular adhesion molecule-1, stimulate CXCR4+ progenitors and allow for solid attachment to endothelial cells. Transplanted cells in circulation interact with BM vascular endothelial cells via "rolling" on endothelial (E) and platelet (P) selectins that are constitutively produced. Insufficiently CXCR4-expressed cells separate and reassert themselves into the circulation.[10] SDF-1 stops CXCR4+ stem cells in humans, allowing them to pass through extracellular BM matrix barriers and enter the hematopoietic compartments. The binding of CD34+ cells to the extracellular matrix protein fibronectin is stimulated by SDF-1 and macrophage inflammatory protein-1 via very late activation antigen-5 (VLA)-5 and VLA-4 integrin receptors.[11] In "stem cell niches," where they interact with supportive cells, adhesion molecules, SDF-1, and growth factors, migratory stem cells finally arrive.

The homing process depletes the transplanted hematopoietic progenitors, which represent only a minor portion of the transplant recipient's stem cell pool. When mature compartments are completely reconstructed, genuine stem cells return to a latent condition and divide slowly,[12,13] preventing exhaustion. The infused HSCs produce enough progenitors to replenish the host hematopoietic system with mature cells despite the unfavourable BM niche conditions. Within two years following transplantation, granulocyte-macrophage colony-forming units are back to normal levels.

Rationale for Hematopoietic Stem Cell Transplantation – How Transplantation Works

The reasons for hematopoietic stem cell transplantation (HSCT) are determined by the patient's health, the treatment goals, and the accessibility and origin of stem cells (Table 1). Hematological malignancies (including premalignant diseases) are the most frequent indications for allogeneic HSCT, according to data gathered in 2006 by the Center for International Blood and Marrow Transplant Research (IBMTR) from more than 400 transplant facilities across the world. Acute lymphoblastic leukaemia (ALL) makes up 16% of allogeneic HSCTs, chronic myeloid leukaemia (CML) 6%, various leukemias and preleukemias (18%), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) 12%, and multiple myeloma (MM) 3%. Acute myeloid leukaemia (AML) makes up 33%.

In the 1980s and the beginning of the 1990s, the use of allogeneic HSCT for haematological malignancies was primarily limited to younger patients (#45 years old) with a sibling donor who shared the same human leukocyte antigen (HLA). The use of allogeneic HSCT in elderly patients has increased thanks to less strenuous precondition regimens, better prophylaxis for graftversus-host disease (GvHD), and supportive care. Only 4% of allogeneic HSCT patients between 1987 and 1992 were above 50. 33% and 11%, respectively, of allogeneic HSCT recipients in 2006 were beyond the age of 50.

Large unrelated donor registries, like the Anthony Nolan Trust in the United Kingdom, have made it easier to use HSCT in patients without HLA-identical siblings. In 2006, more over 40% of HSCTs for hematological malignancies were performed on unrelated donors, compared to less than 10% between 1987 and 1992. Higher chemotherapy doses that would be lethal in a traditional environment can be used thanks to HSCT. After the induction of lethal myelosuppression, autologous or allogeneic HSCs are employed as a "rescue." When there is a direct relationship between chemotherapy dose and tumour response and when myelosuppression is the dose-limiting side effect of the treatment, autologous HSCT is most successful. When there is a direct relationship between chemotherapy dose and tumour response and when myelosuppression is the dose-limiting side effect of the treatment, autologous HSCT is most successful. The conditioning procedure in allogeneic HSCT eliminates cancerous cells, inefficient hematopoietic cells, and host immune cells that might reject the donor cells. HSCT was once thought of as a technique to save patients from therapy-induced marrow aplasia, but it is now recognised that alloreactive donor cells have a significant graft-versus-tumor (GvT) effect that aids in the elimination of cancer.

www.ijprt.com https://doi.org/10.5281/zenodo.7461148

In addition, HSCT is a well-proven therapy for autoimmune diseases, immunodeficiency conditions, and congenital or acquired BM failure. [14] In these situations, the GvT effect is undesirable, and GvHD prevention is a top concern. HSCs can also serve as "therapeutic vehicles" to introduce genes that promote antitumor activity or to replace missing or ineffective enzymes, such as adenosine deaminase (eg, interleukin-2). To optimize the GvT impact and incorporate "death genes" for donor cell elimination in the event of GvHD, infused HSCs can be genetically altered. 15,16 Since microchimerism makes it easier to build transplanted organ tolerance, lymphohematopoietic cells can be employed in conjunction with solid organ transplants. [17]

Hematopoietic stem and progenitor cells from donor marrow or other sources are intravenously infused during allogeneic HSCT. The stem cells engraft in the BM niches and "home" to the recipient's hematopoietic milieu. [18] In ideal conditions, the immune system of the recipient accepts donor cell engraftment without nonengraftment or late graft failure. Immune effector cells from the donor engage with immune cells from the recipient and sustainably engraft without causing deadly GvHD. Eventually, a stable chimeric state takes control, accompanied by a persistent GvT impact and the restoration of functioning B lymphocytes, T lymphocytes, and natural killer cells. [19]

Kolb et al.'s[20] findings that chronic myelogenous leukaemia relapses following allogeneic transplantation may be treated with an infusion of lymphocytes from the original donor offered strong support for an immunotherapeutic GvT impact.

Choosing a Stem Cell Source

The three HSC subcategories are allogeneic, syngeneic, and autologous. The availability of donors and the purpose of the transplant will determine the HSC source to be used. The use of autologous HSCs is frequently prohibited by extensive past cytotoxic therapy and severe malignant involvement of the marrow or peripheral blood. For allogeneic transplants, sibling donors who are HLA-matched are desired; unfortunately, fewer than 30% of patients have a compatible donor. [21] Through volunteer registries, patients without siblings have a 30%–40% chance of obtaining an unrelated, phenotypically HLA-matched donor. [22] The emergence of cord blood HSCs has enhanced the likelihood that both paediatric and adult patients may find allogeneic donors. [23–25]

In order to treat malignant haematological and non-hematological disorders, myeloablative chemotherapy is often used. Autologous, syngeneic, or allogeneic HSCs enhance hematopoietic recovery after this treatment. For the treatment of congenital hematopoietic or immunological abnormalities as well as acquired diseases of marrow function, such as aplastic anaemia, syngeneic or allogeneic HSCs are employed (eg, thalassemia and severe combined immunodeficiency syndrome). [26,27]

How Stem Cells for HSCT are Produced

HSC products from BM, peripheral blood, or umbilical cord blood are accessible for autologous or allogeneic transplantation (UCB).

Bone Marrow

Under either epidural or general anaesthesia, BM is extracted from the posterior iliac crests. If more marrow is needed, it might be taken from the sternum or anterior iliac crest. Large-bore needles and heparinized syringes are used to collect the BM, which is then kept in culture medium. After being harvested, the bone marrow can be used right away, but it can also be kept at 4°C for 24 hours without losing its stem cell viability, enabling HSC transfers both domestically and internationally between transplant programmes.

It is unclear what cell dosage is necessary for stable long-term engraftment. Although cell dosages of 1 108/kg are possible, a nucleated cell dose of 2 108/kg is typically regarded as sufficient. 28 700 to 1,500 mL of BM from an adult donor are needed for this. According to National Marrow Donor Program regulations, BM withdrawal is limited to 15 mL/kg of donor weight. Peripheral blood leukocyte numbers are unaffected since just a small portion of the body's total BM is eliminated.

Prior to intravenous transfusion into the recipient, the marrow is filtered to remove any remaining particles

www.ijprt.com https://doi.org/10.5281/zenodo.7461148

or clots after harvesting. If the receiver has significant anti-A or anti-B antibody titers as well as large or minor ABO mismatches, red blood cells and plasma may be reduced. [29] Plasmapheresis of the recipient can lower high anti-A or anti-B titers in the case of a significant ABO mismatch, negating the need for red blood cell reduction of the marrow.

A study of 1,549 donors' marrow harvests found that the median total nucleated cell count was 2.5 108/kg recipient weight (range, 0.3–12.0). 30 Around 0.27–0.4% of marrow harvesting complications are life-threatening, and these problems are primarily related to anaesthetic danger. [31]

Peripheral Blood Stem Cells

The HSCT component for autologous HSCs has almost entirely been replaced by peripheral blood stem cells (PBSCs), which are frequently employed for allogeneic HSCT. More quickly than BM-derived stem cells, PBSCs engraft. The median time to an absolute neutrophil count greater than 500/L and platelet transfusion independence following PBSC trans-plantation is typically between 11 and 14 days. [32,33]

Engraftment kinetics advancements lower the cost of autologous transplantation. [34,35] Due to the low density of peripheral blood HSCs, numerous aphereses are necessary to collect enough of them. By mobilising HSCs to the peripheral circulation using granulocyte colony-stimulating factor (G-CSF) at a rate of 6 g/kg/day with or without chemotherapy, the number of leukaphereses may be decreased to one or two sessions. [36]

After chemotherapy, patients undergo leukapheresis when either the peripheral blood CD34 cell count reaches at least.10/L or the total white blood cell count reaches 1,000/L. Using a continuous blood flow separation approach, leukapheresis can be done as early as day 4. Mobilization is done with G-CSF alone (5-16 g/kg) by daily subcutaneous injections for 5-8 days for healthy allogeneic donors or patients who do not need chemotherapy. [37–39]

The following side effects of G-CSF injection are common: bone pains, which affected 84% of patients; headaches, which affected 54% of patients; weariness, which affected 31% of patients; and nausea, which affected 13% of patients. [40] There are a few instances of nontraumatic splenic rupture, but there are no absolute contraindications to stimulating healthy donors with G-CSF. [41–44]

For frozen preservation before to transplantation, phenesed products can be cryopreserved in 5% dimethoxysulfonic acid (DMSO). The amount of CD34 cells in the hematopoietic cell graft increases (up to 5 106/kg), resulting in more rapid and sustained haematological recovery of neutrophil and platelet counts. 36 Some researchers believe that 2.5 106/kg of recipient weight is the lowest amount of peripheral blood CD34 cells necessary for full autologous recovery.

Allogeneic HSCs can be regularly drawn from peripheral blood since the cell dosage employed in the autologous transplant context results in consistent and rapid engraftment. By doing so, general anaesthesia and other typical marrow harvesting complications including back discomfort, exhaustion, and bleeding from the harvest site are avoided. A large-bore vascular access double-lumen catheter can be necessary if the patient's peripheral veins are insufficient.

For autologous or allogeneic transplantation, the drawbacks of PBSC components over BM or UCB include multiday collections (especially for autologous transplantation), the inability to collect enough components from all patients and donors, and a slightly higher risk of GvHD that is challenging to treat.[45, 46]

Umbilical Cord Blood

Lack of an HLA donor who is properly matched reduces the possibility of receiving an allogeneic HSCT, especially for ethnic minorities. The growth of cord blood banks, like the recently inaugurated Anthony Nolan Cord Blood Bank at Nottingham Trent University in the United Kingdom, which will bank stem cells from 50,000 cord bloods by 2013, is one way to address the donor scarcity.

Important advantages of cord blood transplantation (CBT) include quick and safe procurement, accessibility, reduced risk of viral transmission, and

 https://doi.org/10.5281/zenodo.7461148

relatively immature immune cells that lower the prevalence of GvHD. [47] However, CBTs have fewer cells than other HSCT cell sources, which slows down haematological healing, raises the risk of infection, and increases mortality during the first posttransplantational period. [48]

For patients lacking a qualified related or unrelated volunteer, CBT has filled a critical need. Multiple-antigen mismatches are possible because the donor cells are immunologically relatively immature. For CBT to be effective and to lower the risk of GvHD, a match of three to four of the six HLA-A, HLA-B, and HLA-DRB1 antigens is required.

Compared to bone marrow or peripheral blood, cord blood has a higher enrichment of stem cells. [48,49] The moment the chord is clamped and severed, 40–70 mL of fetal cord blood are taken. The UCB cells are gathered into a sterile donor blood collecting kit after the placenta has been detached. Blood is drawn from the placenta and umbilical cord using "conventional gravity phlebotomy" and placed in citrate phosphate dextrose (CPD) anticoagulant. 50 The units are kept in cord blood banks after being cry preserved. If the cord is properly clamped, there are no hazards to the donor from the collection.

New culture techniques that boost the quantity of CD34 cord blood progenitors are currently being developed. A phase 1 study resulted in a 100-fold growth of CD34 stem cells, while a recent work using a notch ligand and an ex vivo culture method shown a decrease in neutrophil engraftment times. [51]

The incidence of chronic GvHD (cGvHD) was significantly lower after allogeneic cord blood HSCT, according to a meta-analysis comparing unrelated donor CBT and unrelated donor BM transplantation in adult and paediatric patients (relative risk [RR] 0.41; 95% confidence interval [CI], 0.25-0.68). Adults' overall survival and recurrence rates were also enhanced with BM-derived HSCT (OS). [52]

The Effectiveness and Safety of Bone Marrow Transplants

Patients with chemotherapy-resistant haematological malignancies, which are typically deadly without treatment, have just one possibly curative option: HSCT. Both significantly early (100 days after transplant) and late (100 days after transplant) morbidity and mortality have been linked to HSCT. In the first 100 days following autologous or allogeneic HSCT, 4% of patients will pass away. [53] Results for NRM (non-relapse related mortality) can reach 46%. [54]

Comorbidities, illness features, HLA matching, GvHD, the GvT effect, and posttransplantation recurrence all have an impact on HSCT mortality. Relapse-related mortality takes into account patient comorbidities, HSCT-related consequences, and tumour biology. Improvements in tissue typing, preventative measures against viral and fungi infection, immunosuppressive medications, and supportive care all contribute to better results.

Although older patients receiving RIC have a greater relapse rate, the discovery of reduced intensity conditioning (RIC) regimes has made HSCT possible in older patients, who are commonly characterised as those who are 50 years or older. [55] With 5-year survival rates of about 90% for unrelated sibling transplants and 100% for matched sibling donor transplants, the results for children with severe aplastic anaemia are excellent. [56]

Hematologic Cell Transplant Comorbidity Index

Researchers at the Fred Hutchinson Cancer Research Center (Seattle, Washington, USA) created the hematopoietic cell transplantation comorbidity index (HCT-CI) to enable the risk evaluation of patients undergoing transplantation. [57,58] The researchers gathered retrospective data from 1,055 patients who had conditioning procedures before stem cell transplantation that were either nonablative (n = 294) or ablative (n = 761). The group's median age was 45, and the majority of diagnoses (66%) were myeloid malignancies. [57]

To predict 2-year NRM after transplantation, the HCT-CI employs a comorbidity-based scoring system that accounts for age, disease risk, and conditioning regimens. Three risk categories are used to categorise patients: low risk (NRM, 14% at 2 years), intermediate risk (NRM, 21% at 2 years), and high risk (NRM, 41% at 2 years). [57] In a group of 203

 https://doi.org/10.5281/zenodo.7461148

patients with NHL, HL, MM, and patients with myelodysplastic syndromes or AML receiving alemtuzumab-based RIC HSCT, the HCT-CI successfully predicted NRM, OS, and progression-free survival.[55]

Other researchers have questioned the HCT-capacity CI's to predict NRM and OS, despite the fact that it is an effective predictor of outcome. [60] In a cohort of 444 adult allogeneic HCT recipients, Defor et al.[60] introduced the modified comorbidity index (MCI), which was created using a pure multiplicative model. When compared to the HCT-CI, the MCI demonstrated more OS and NRM discriminating and predictive capacity. The HCT-CI and MCI need to be further validated in larger HSCT cohorts.

The HSCT's Drawbacks

The prolonged immunodeficiency and significant drug toxicities brought on by the large chemotherapeutic doses utilised in HSCT necessitate a protracted healing period. The ability to create supportive-care regimens that are risk-specific helps to lower the incidence of transplantation morbidity and mortality. Infections, early noninfectious complications (occurring within 3 months of HSCT), late noninfectious problems (occurring after 3 months of HSCT), and GvHD are the main categories for HCT-related issues.

After HCT, Infection

After HSCT, infection is a significant factor in morbidity and mortality. Engraftment happens 7–14 days after autologous HSCT and 14–28 days after allogeneic HSCT. Pre-engraftment, which is defined as the time period before engraftment, is less than three weeks; immediate postengraftment, which is defined as the time period between 3 weeks and three months; and late postengraftment, which is defined as the time period after three months. Allogeneic transplant recipients are susceptible to infection at all times, but autologous transplant recipients are only seriously at risk before engraftment and right after engraftment. The rupture of mucocutaneous barriers, indwelling venous catheters, neutropenia, and organ failure are infection risk factors during the pre-engraftment phase.

Although there are no specific biomarkers for immunological reconstitution that can predict infection risk and the requirement for antimicrobial prophylaxis, total T cell (CD3) or CD4 cell numbers can be used as a stand-in for T-cell immunity. Patients must therefore be carefully monitored and treated as soon as any infection-related signs or symptoms arise. Following the first posttransplant period and 3-6 months after the end of immunosuppression, the majority of facilities continue antimicrobial prophylaxis.

At one year after the transplant, vaccines may be provided to HSCT survivors. On www.cdc.gov, you can find the most recent recommendations for treating infections in HCT patients from the Centers for Disease Control and Prevention, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation.

Up to 30% of transplant recipients get bacterial infections during the first few weeks after their transplant, most frequently from coagulase-negative Staphylococcus in the oropharynx and gastrointestinal tract (Streptococcus viridans, Enterococcus species, and enteric gram-negative bacilli). Pseudomonas aeruginosa, Enterobacteriaceae, and Stenotrophomonas maltophilia are three more gram-negative bacteria that can cause significant illnesses. Clostridium difficile is the most frequent cause of infectious diarrhoea. Patients are at risk of developing unique nosocomially acquired infections such legionella as well as septicemia and meningitis from Listeria monocytogenes. [61]

After HCT, fungal and Aspergillus species infections are frequent. Prolonged severe neutropenia, the use of broad-spectrum antibiotics, severe organ dysfunction, mucocutaneous injury, and Candida species yeast infection are risk factors for invasive candidiasis. Invasive candidiasis' morbidity and mortality are decreased by the introduction of standard antifungal prophylaxis using triazole antibiotics, particularly fluconazole. However, triazole-resistant Candida species including C. krusei and C. glabrata have become more common sources of infections. [62]

Mucocutaneous injury, cellular immune logical dysfunction, immune modulating viral infections

 https://doi.org/10.5281/zenodo.7461148

including cytomegalovirus (CMV) and human herpes 6 viruses, hyposplenism, and impaired opsonization and reticuloendothelial function are risk factors for infection in the immediate postengraftment phase. Acute and chronic GvHD, corticosteroids, and immunosuppressive medications all worsen and lengthen severe immune dysfunction. [63]

Allogeneic HSCs take longer to engraft and rebuild immunity than autologous HSCs, increasing the risk of infection. Immune reconstitution after allogeneic HSCT can take up to two years. Patients who need long-term immune suppression for cGvHD are especially vulnerable to infection with encapsulated bacteria, fungi, and viruses, including Streptococcus pneumonia, Neisseria meningitides, Haemophilus influenzae, and P. jirovecii (CMV and varicella zoster virus). Using an unrelated donor and perhaps cord blood stem cells are additional factors that prolong immunological deficits. Other risks include donor - recipient HLA difference, graft manipulation using T cell depletion, and graft manipulation.

A major cause of morbidity and mortality after HSCT is primary Epstein-Barr virus (EBV) infection or reactivation of latent CMV or human herpes virus infections. In particular, for illnesses like EBV and varicella zoster virus, patients should get education about how to lower their risk of developing new viral infections.

Since practically all herpes infections result from viral reactivation rather than a new primary infection, the danger of herpes virus infection is primarily limited to seropositive patients. After autologous or allogeneic transplantation, reactivation rates are similar at 70%. Herpes simplex virus infections typically take 2–3 weeks to manifest, while CMV infections take about 100 days.

After HSCT, CMV infection is a frequent cause of morbidity and mortality. CMV is a contagious disease that affects 50% to 85% of the general population and is spread by saliva, intercourse, and blood products. About 30% of patients who undergo allogeneic HSCT will reactivate latent CMV infection, which typically happens in the late posttransplant phase and is linked to a 46% mortality. [64]

The cellular immune system plays a major role in mediating the immunological response against CMV. The virus establishes lifelong latency after the initial infection and immune response. Immunocompetent people with primary CMV infection typically have no symptoms, whereas immune compromised patients with primary CMV infection or reactivation may experience severe disease. When a CMV-negative recipient receives an allograft from a CMV-positive donor or after the depletion of CMV-specific T cells, reactivation happens in allogeneic transplantation.

After HSCT, pneumonitis, retinitis, hepatitis, colitis, and BM suppression can all result from CMV infection or reactivation. The presence of GvHD, prolonged and persistent neutropenia, CMV viremia, and receiving a CMV-positive transplant are all risk factors for CMV infection. Phosphoprotein 65 (pp65) antigenemia, which is a plentiful CMV viral matrix protein and an immunodominant CMV antigen, can be used to follow patients serologically for early indications of relapse. When leukocyte counts are insufficient for CMV pp[65] antigenemia testing due to severe neutropenia, quantitative plasma polymerase chain reactions for CMV DNA may be helpful.

By pairing CMV-positive donors with CMV-positive receivers and CMV-negative donors with CMV-negative recipients, the risk of CMV infection can be decreased. Prophylaxis is preferable to early CMV treatment since antiviral medications are harsh, challenging to deliver, and only partially effective. [65] The antiviral medication ganciclovir suppresses the immune system, results in neutropenia, and hinders the recovery of CMV-specific cells. 66 Immunoglobulins given as a preventative measure to patients at high risk do not lower the likelihood of CMV infection. [67]

Vaccination strategies to prevent CMV infections in patients undergoing HSCT and solid organ transplants, as well as neonatal CMV infection, have been the subject of substantial investigation. [68] Due in part to the difficult process of identifying CMV vaccine epitopes[69] and the fact that new infections can occur with various virus strains, development of a successful CMV immunization has been sluggish. The primary immune dominant CMV antigen and potential

 https://doi.org/10.5281/zenodo.7461148

target for a peptide-based CMV vaccination is the viral coat phosphoprotein pp65. [69] An early termination of a recent placebo-controlled Phase II clinical trial of a CMV glycoprotein vaccine was due to its encouraging effectiveness of about 50%. 70 Phase III research has started.

Adoptive cellular transfer therapy can be used to treat and prevent CMV infection as well as other transplant-related illnesses such lymphoproliferative disorders caused by the EBV virus. The conditioning produced by the HSCT provides a "vacated area" within the BM, which enables the rapid proliferation of adoptively transferred cells. This creates a distinctive immunological milieu. Clinical trial results have been encouraging, but technological challenges, like finding qualified donors and producing antigen-specific T cells from patients or donors, have limited acceptance. [68]

Even beyond the first two years following transplantation, many HSCT patients still have immune compromised states. This is especially true for people with cGvHD, where infection still accounts for the majority of morbidity and mortality. To enable rapid immune reconstitution protection against infectious pathogens, to find trustworthy surrogate markers of immunological recovery, and to safely increase the GvT response, research and innovative therapeutics are required.

Graft-Versus-Host Illness

Acute GvHD (aGvHD), which happens within 100 days of transplantation, and chronic GvHD (cGvHD), which happens after 100 days, are two different types of GvHD. This distinction is arbitrary because cGvHD symptoms can appear within 100 days of transplant while aGvHD symptoms can appear as early as 3 months following RIC. The recent National Institutes of Health (NIH) Consensus Conference recommended definitions of aGvHD or cGvHD, each with two subcategories, utilising the specificity of signs and symptoms rather than time of onset[71]. This is because aGvHD and cGvHD have common traits.

Acute GvHD

According to a number of risk variables, the overall incidence of clinically relevant (grade II–IV) aGvHD ranges from 10% to 80%. Increasing host age, graft type (cord blood has a lower rate, and PBSCs have a higher rate when compared with BM-derived grafts), donor and host CMV status, donor and recipient gender disparity, all immunization of the donor (e.g., multiparous females), donor and recipient gender disparity, donor and recipient CMV status, and conditioning regimen are risk factors for aGvHD. [72,73] Some HLA alleles are linked to stronger (HLA-A10 and HLA-B7) or lesser (HLA-B27) graft-versus-host responses even when fully matched. [74]

The Identification and Evaluation of a GvHD

aGvHD typically affects the skin, liver, gastrointestinal tract, and hematopoietic system[75] and manifests as an abnormal liver function test, a recognisable rash, and abdominal pain and diarrhoea. Fever, a decline in performance level, and weight loss are other symptoms. The differential is often broad, which makes diagnosis challenging. A biopsy of the epidermis or digestive system can either support or refute the diagnosis of aGvHD. Percutaneous transjugular liver biopsy may be preferable to percutaneous liver biopsy in patients with thrombocytopenia. [76]

From clinically minor grades 0 or I disease to clinically substantial grades II-IV disease, the severity of aGvHD varies. Glucksberg published the initial aGvHD categorization in 1974. [77] The Glucksberg classification rates each organ on a scale of 0 to 4 based on its function and performance status. The combined organ stages result in an overall grade of aGvHD.

The Glucksberg system has drawbacks, and in 1994, a modified grading system was proposed in a consensus workshop. This approach kept the objective Glucksberg organ-staging criteria but did not include the subjective performance status criterion (Table 5). [78] The International Bone Marrow Transplant Registry has since created an updated system. [79]

Treatment and Prevention

The primary factor in early transplant-related mortality is aGvHD, which is brought on by both the disease itself and treatment-related complications such significant immunological dysfunction and

opportunistic infections that prevent the GvT impact from being beneficial. As second-line treatments are ineffective, the primary
response to treatment is the most crucial indicator of long-term survival.

T-cell depletion and pharmaceutical therapy are the two main strategies for preventing GvHD after BM transplantation. A combination of a calcineurin inhibitor (cyclosporine [CsA] or tacrolimus) and "short course" methotrexate is the recommended pharmacological therapy (MTX). After an ablative conditioning regimen, this regimen is active and provides a reasonable balance between the GvHD and GvT impact in matched sibling transplants. [80]

Methylprednisolone and a calcineurin inhibitor are the primary treatments for aGvHD, which are given for 7–14 days and then gradually tapered off of after a patient has reached a full therapeutic response, which happens in 25%–40% of patients with grade II–IV aGvHD. High-dose methylprednisolone, tacrolimus, mycophenolate mofetil, antithymocyte globulin, monoclonal antibodies such those against the interleukin-2 (IL-2) receptor, the tumour necrosis factor (TNF), and the CD52, pentostatin, and extracorporeal photopheresis are examples of second-line therapies. 81 There are no standards for determining which patients are most likely to benefit from second-line therapy. [80,82]

Chronic GvHD

Around 50% of long-term recipients of HLA-identical sibling transplants experience cGvHD83, which is the main factor in late morbidity and NRM in transplant recipients. Due to the identical organs that both disorders affect, the clinical symptoms may be overlapping with aGvHD. Systemic lupus erythematosus, scleroderma, sicca syndrome, eosinophilic fasciitis, rheumatoid arthritis, primary biliary sclerosis, bronchiolitis obliterans, and immunological cytopenias are among the numerous characteristics of cGvHD that resemble autoimmune diseases. [83–85]

Prior a GvHD, a greater degree of HLA mismatch, an older donor or host, subacute GvHD on skin biopsy or buccal mucosal biopsy, CMV seropositivity (donor and recipient), and regimens incorporating total body irradiation are major risk factors for the development of cGvHD. 83,84,86,87 Second BM infusions, an active herpes virus infection before the transplant, the type of underlying cancer, the gender of the recipient and donor, and a lack of prior blood transfusions are all predictive factors. [83]

The cGvHD Diagnosis

Skin, gastrointestinal, and serum bilirubin concentration involvement are all signs of cGvHD. Histological confirmation is frequently required to support a clinical impression of potential cGvHD because the clinical diagnosis is one of exclusion.

NIH Consensus Requirements

cGvHD diagnostic standards have been developed by an NIH consensus development effort for use in clinical trials71:

- The two main classifications of cGvHD are (1) classic cGvHD (without aGvHD-specific traits or symptoms), and (2) an overlap syndrome, in which both aGvHD and cGvHD co-occur.
- Alternative diagnosis must be ruled out.
- There is no time frame established for cGvHD diagnosis.
- There must be at least one distinct manifestation, such as keratoconjunctivitis sicca, which should be verified by biopsy or other pertinent testing, or at least one definitive clinical symptom of cGvHD, such as poikiloderma or an esophageal web (eg, Schirmer test).

Therapy for cGvHD

The typical first-line treatment for cGvHD has been a CsA and prednisolone combination for almost 20 years. 88 For cGvHD that returns or does not respond to initial therapy, there is no conventional treatment. Psoralen with ultraviolet light, mycophenolate mofetil, thalidomide, plaquenil, pentostatin, extracorporeal photochemotherapy,89 and rituximab are a few examples of experimental treatments. [90]

Rates of Morbidity and Mortality

Because of improved conditioning regimens, HLA typing, supportive care, and the prevention and

 https://doi.org/10.5281/zenodo.7461148

treatment of serious infections, the mortality and morbidity rates associated with transplantation have decreased significantly. Depending on the illness stage and histology, overall and event-free survival rates can vary. The patients who receive sibling allogeneic transplants who are HLA matched have the highest 5-year survival rates. 91 Given the differences in study design, survival measurement, and follow-up duration, these data should be taken with care. [92]

HSCT is associated with early morbidity, although most transplant recipients experience high levels of physical and mental well-being (QoL). After 3-5 years following transplantation, more than 90% of patients resume full-time employment. When compared to an age-matched general population, disease-free patients have a 10-fold higher chance of dying at 2 years after allogeneic HSCT. Even fifteen years after the transplant, mortality rates are still high.

Secondary malignancies, cGvHD, late infections without GvHD, late recurrence of the original malignant disease, pulmonary problems, and cardiac issues are the main reasons of death. Many years after receiving HSCT, functional problems affect up to 20% of long-term survivors. Treatment-related side effects, immune dysfunction, autoimmune syndromes, problems with children's growth, cognitive dysfunction, second malignancies, chronic GvHD, and issues with psychosocial adjustment are examples of late consequences. The execution of daily tasks, feelings of personal wellbeing, and interpersonal and familial connections can all be adversely affected by these late consequences.

QoL comprises physical capabilities, symptoms, social well-being, psycho-emotional condition, and spiritual or existential qualities. It refers to all aspects of life, excluding length. After HSCT, quality of life (QoL) might be completely normal with no physical, mental, or social aftereffects and a better appreciation for life, or it can be substantially diminished with physical impairment, pain, and psychological anguish. Even though long-term survivors describe a variety of distinct symptoms and limits in everyday activities, almost all say they would have the treatment done again in the same situation. Older age, advanced disease at transplantation, cGvHD, and late side effects are the main risk factors for poor quality of life (QoL) after HSCT. [96,97] Health and functional status increase with GvHD resolution, despite the fact that cGvHD is a substantial predictor of poor QoL. [98,99]

There are gender-specific disparities in QoL that have been noted, with females being more prone to report sexual and psychological difficulties. [94] 30% to 60% of HSCT survivors have been found to suffer cognitive abnormalities, notably those involving executive function, memory, and motor skills. [100] Older transplant recipients, conditioning methods based on total body irradiation, and CsA usage all carry a higher risk of developing cognitive sequelae. Patients could require yearly testing for depression and other psychological symptoms, as well as therapy for psychological issues.

Even after a full recovery, allogeneic HSCT patients must visit the hospital sometimes. For the patient, their family, primary care physicians, and the transplantation team, allogeneic HSCT is a lifetime commitment. Long-term follow-up of survivors after HSCT requires robust mechanisms.

Conclusion

Both the biological understanding of HSCs and the medical supervision of HSCT patients have made significant strides. With the introduction of cord blood banking, more patients will be able to get allogeneic transplants from unrelated donors, and a priceless resource for scientific research will be made available. The introduction of RIC regimens is exciting and provides elderly patients who would not have been candidates for HSCT with the possibility of remissions. Maximizing the GvT impact while reducing the danger of acute and chronic GvHD may be the biggest outstanding difficulty. More fundamental scientific investigation will outline the immunological mechanisms underlying GvHD and result in more effective medicinal treatments.

 https://doi.org/10.5281/zenodo.7461148

Acknowledgement

The authors are thankful to the MET Institute of pharmacy Adagaon, Nashik (India) for unconditional support for the work.

References

1. Bryder, D., Rossi, D.J. And Weissman, I.L., 2006. Hematopoietic Stem Cells: The Paradigmatic Tissue-Specific Stem Cell. *The American Journal Of Pathology*, *169*(2), Pp.338-346.
2. Shizuru, J.A., Negrin, R.S. And Weissman, I.L., 2005. Hematopoietic Stem And Progenitor Cells: Clinical And Preclinical Regeneration Of The Hematolymphoid System. *Annual Review Of Medicine*, *56*, P.509.
3. Ogawa, M., 1993. Differentiation And Proliferation Of Hematopoietic Stem Cells.
4. Alcorn, M.J., Holyoake, T.L., Richmond, L., Pearson, C., Farrell, E., Kyle, B., Dunlop, D.J., Fitzsimons, E., Steward, W.P., Pragnell, I.B. And Franklin, I.M., 1996. CD34-Positive Cells Isolated From Cryopreserved Peripheral-Blood Progenitor Cells Can Be Expanded Ex Vivo And Used For Transplantation With Little Or No Toxicity. *Journal Of Clinical Oncology*, *14*(6), Pp.1839-1847.
5. Zandstra, P.W., Lauffenburger, D.A. And Eaves, C.J., 2000. A Ligand-Receptor Signaling Threshold Model Of Stem Cell Differentiation Control: A Biologically Conserved Mechanism Applicable To Hematopoiesis. *Blood, The Journal Of The American Society Of Hematology*, *96*(4), Pp.1215-1222.
6. Hatzimichael, E. And Tuthill, M., 2010. Hematopoietic Stem Cell Transplantation. *Stem Cells And Cloning: Advances And Applications*, *3*, P.105.
7. Lanzkron, S.M., Collector, M.I. And Sharkis, S.J., 1999. Homing Of Long-Term And Short-Term Engrafting Cells In Vivo A. *Annals Of The New York Academy Of Sciences*, *872*(1), Pp.48-56.
8. Aiuti, A., Webb, I.J., Bleul, C., Springer, T. And Gutierrez-Ramos, J.C., 1997. The Chemokine SDF-1 Is A Chemoattractant For Human CD34+ Hematopoietic Progenitor Cells And Provides A New Mechanism To Explain The Mobilization Of CD34+ Progenitors To Peripheral Blood. *The Journal Of Experimental Medicine*, *185*(1), Pp.111-120.
9. Aiuti, A., Tavian, M., Cipponi, A., Ficara, F., Zappone, E., Hoxie, J., Peault, B. And Bordignon, C., 1999. Expression Of CXCR4, The Receptor For Stromal Cell-Derived Factor-1 On Fetal And Adult Human Lymphohematopoietic Progenitors. *European Journal Of Immunology*, *29*(6), Pp.1823-1831.
10. Peled, A., Kollet, O., Ponomaryov, T., Petit, I., Franitza, S., Grabovsky, V., Slav, M.M., Nagler, A., Lider, O., Alon, R. And Zipori, D., 2000. The Chemokine SDF-1 Activates The Integrins LFA-1, VLA-4, And VLA-5 On Immature Human CD34+ Cells: Role In Transendothelial/Stromal Migration And Engraftment Of NOD/SCID Mice. *Blood, The Journal Of The American Society Of Hematology*, *95*(11), Pp.3289-3296.
11. Lapidot, T. And Kollet, O., 2002. The Essential Roles Of The Chemokine SDF-1 And Its Receptor CXCR4 In Human Stem Cell Homing And Repopulation Of Transplanted Immune-Deficient NOD/SCID And NOD/SCID/B2mnull Mice. *Leukemia*, *16*(10), Pp.1992-2003.
12. Lanzkron, S.M., Collector, M.I. And Sharkis, S.J., 1999. Hematopoietic Stem Cell Tracking In Vivo: A Comparison Of Short-Term And Long-Term Repopulating Cells. *Blood, The Journal Of The American Society Of Hematology*, *93*(6), Pp.1916-1921.
13. Mahmud, N., Devine, S.M., Weller, K.P., Parmar, S., Sturgeon, C., Nelson, M.C., Hewett, T. And Hoffman, R., 2001. The Relative Quiescence Of Hematopoietic Stem Cells In Nonhuman Primates. *Blood, The Journal Of The American Society Of Hematology*, *97*(10), Pp.3061-3068.
14. Gratwohl, A., Passweg, J., Gerber, I. And Tyndall, A., 2001. Stem Cell Transplantation For Autoimmune Diseases. *Best Practice & Research Clinical Haematology*, *14*(4), Pp.755-776.
15. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C. And Bordignon, C., 1997. HSV-TK Gene Transfer Into Donor Lymphocytes For Control Of Allogeneic Graft-Versus-Leukemia. *Science*, *276*(5319), Pp.1719-1724.
16. Cohen, J.L., Boyer, O., Salomon, B., Onclercq, R., Charlotte, F., Bruel, S., Boisserie, G. And Klatzmann, D., 1997. Prevention Of Graft-Versus-Host Disease In Mice Using A Suicide Gene Expressed In T Lymphocytes. *Blood, The Journal Of The American Society Of Hematology*, *89*(12), Pp.4636-4645.
17. Gandy, K.L. And Weissman, I.L., 1998. Tolerance Of Allogeneic Heart Grafts In Mice Simultaneously Reconstituted With Purified Allogeneic Hematopoietic Stem CELLS1. *Transplantation*, *65*(3), Pp.295-304.
18. Quesenberry, P.J., Dooner, G., Colvin, G. And Abedi, M., 2005. Stem Cell Biology And The Plasticity Polemic. *Experimental Hematology*, *33*(4), Pp.389-394.
19. Abrahamsen, I.W., Somme, S., Heldal, D., Egeland, T., Kvale, D. And Tjonnfjord, G.E., 2005. Immune Reconstitution After Allogeneic Stem Cell Transplantation: The Impact Of Stem Cell Source And Graft-Versus-Host Disease. *Haematologica*, *90*(1), Pp.86-93.
20. Kolb, H.J., Mittermüller, J., Clemm, C.H., Holler, E., Ledderose, G., Brehm, G., Heim, M. And Wilmanns, W., 1990. Donor Leukocyte Transfusions For Treatment Of

Recurrent Chronic Myelogenous Leukemia In Marrow Transplant Patients. *Blood*, *76*(12), Pp.2462-2465.

21. Anasetti, C. And Hansen, J.A., 1994. Effect Of HLA Incompatibility In Marrow Transplantation From Unrelated And HLA-Mismatched Related Donors. *Transfusion Science*, *15*(3), Pp.221-230.
22. Anasetti, C., Petersdorf, E.W., Martin, P.J., Woolfrey, A. And Hansen, J.A., 2001. Trends In Transplantation Of Hematopoietic Stem Cells From Unrelated Donors. *Current Opinion In Hematology*, *8*(6), Pp.337-341.
23. Broxmeyer, H.E., Cooper, S., Hangoc, G., Gluckman, E., Auerbach, A., Douglas, G.W., Friedman, H., Kurtzberg, J., Bard, J. And Boyse, E.A., 1990. Human Umbilical Cord Blood: A Clinically Useful Source Of Transplantable Hematopoietic Stem/Progenitor Cells. *The International Journal Of Cell Cloning*, *8*(S1), Pp.76-91.
24. Kurtzberg, J., Laughlin, M., Graham, M.L., Smith, C., Olson, J.F., Halperin, E.C., Ciocci, G., Carrier, C., Stevens, C.E. And Rubinstein, P., 1996. Placental Blood As A Source Of Hematopoietic Stem Cells For Transplantation Into Unrelated Recipients. *New England Journal Of Medicine*, *335*(3), Pp.157-166.
25. Wagner, J., Steinbuch, M., Kernan, N., Broxmayer, H. And Gluckman, E., 1995. Allogeneic Sibling Umbilical-Cord-Blood Transplantation In Children With Malignant And Non-Malignant Disease. *The Lancet*, *346*(8969), Pp.214-219.
26. Fischer, A., Griscelli, C., Landais, P., Friedrich, W., Goldman, S.F., Morgan, G., Levinsky, R., Gerritsen, B., Vossen, J., Fasth, A. And Porta, F., 1990. European Experience Of Bone-Marrow Transplantation For Severe Combined Immunodeficiency. *The Lancet*, *336*(8719), Pp.850-854.
27. Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Politi, P., Durazzi, S.M.T., Muretto, P. And Albertini, F., 1990. Bone Marrow Transplantation In Patients With Thalassemia. *New England Journal Of Medicine*, *322*(7), Pp.417-421.
28. Bahçeci, E., Read, E.J., Leitman, S., Childs, R., Dunbar, C., Young, N.S. And Barrett, A.J., 2000. CD34+ Cell Dose Predicts Relapse And Survival After T-Cell-Depleted HLA-Identical Haematopoietic Stem Cell Transplantation (HSCT) For Haematological Malignancies. *British Journal Of Haematology*, *108*(2), Pp.408-414.
29. Schwella, N., Rick, O., Heuft, H.G., Miksits, K., Zimmermann, R., Zingsem, J., Eckstein, R. And Huhn, D., 1998. Bacterial Contamination Of Autologous Bone Marrow: Reinfusion Of Culture-Positive Grafts Does Not Result In Clinical Sequelae During The Posttransplantation Course. *Vox Sanguinis*, *74*(2), Pp.88-94.
30. Hatzimichael, E. And Tuthill, M., 2010. Hematopoietic Stem Cell Transplantation. *Stem Cells And Cloning: Advances And Applications*, *3*, P.105.
31. Bortin, M.M. And Buckner, C.D., 1983. Major Complications Of Marrow Harvesting For Transplantation. *Experimental Hematology*, *11*(10), Pp.916-921.
32. Bensinger, W., Singer, J., Appelbaum, F., Lilleby, K., Longin, K., Rowley, S., Clarke, E., Clift, R., Hansen, J. And Shields, T., 1993. Autologous Transplantation With Peripheral Blood Mononuclear Cells Collected After Administration Of Recombinant Granulocyte Stimulating Factor.
33. Sheridan, W.P., Fox, R.M., Begley, C.G., Maher, D., Mcgrath, K.M., Juttner, C.A., To, L.B., Szer, J. And Mostyn, G., 1992. Effect Of Peripheral-Blood Progenitor Cells Mobilised By Filgrastim (G-CSF) On Platelet Recovery After High-Dose Chemotherapy. *The Lancet*, *339*(8794), Pp.640-644.
34. Hartmann, O., Corroller, A.G.L., Blaise, D., Michon, J., Philip, I., Norol, F., Janvier, M., Pico, J.L., Baranzelli, M.C., Rubie, H. And Coze, C., 1997. Peripheral Blood Stem Cell And Bone Marrow Transplantation For Solid Tumors And Lymphomas: Hematologic Recovery And Costs: A Randomized, Controlled Trial. *Annals Of Internal Medicine*, *126*(8), Pp.600-607.
35. Vellenga, E., Van Agthoven, M., Croockewit, A.J., Verdonck, L.F., Wijermans, P.J., Van Oers, M.H.J., Volkers, C.P., Van Imhoff, G.W., Kingma, T., Uyl-De Groot, C.A. And Fibbe, W.E., 2001. Autologous Peripheral Blood Stem Cell Transplantation In Patients With Relapsed Lymphoma Results In Accelerated Haematopoietic Reconstitution, Improved Quality Of Life And Cost Reduction Compared With Bone Marrow Transplantation: The Hovon 22 Study. *British Journal Of Haematology*, *114*(2), Pp.319-326.
36. Weaver, C.H., Hazelton, B., Birch, R., Palmer, P., Allen, C., Schwartzberg, L. And West, W., 1995. An Analysis Of Engraftment Kinetics As A Function Of The CD34 Content Of Peripheral Blood Progenitor Cell Collections In 692 Patients After The Administration Of Myeloablative Chemotherapy.
37. Bensinger, W.I., Martin, P.J., Storer, B., Clift, R., Forman, S.J., Negrin, R., Kashyap, A., Flowers, M.E., Lilleby, K., Chauncey, T.R. And Storb, R., 2001. Transplantation Of Bone Marrow As Compared With Peripheral-Blood Cells From HLA-Identical Relatives In Patients With Hematologic Cancers. *New England Journal Of Medicine*, *344*(3), Pp.175-181.
38. Korbling, M., Przepiorka, D., Huh, Y.O., Engel, H., Van Besien, K., Giralt, S., Andersson, B., Kleine, H.D., Seong, D. And Deisseroth, A.B., 1995. Allogeneic Blood Stem Cell Transplantation For Refractory Leukemia And Lymphoma: Potential Advantage Of Blood Over Marrow Allografts [See Comments].
39. Schmitz, N., Bacigalupo, A., Hasenclever, D., Nagler, A., Gluckman, E., Clark, P., Bourquelot, P., Greinix, H., Frickhofen, N., Ringden, O. And Zander, A., 1998.

Allogeneic Bone Marrow Transplantation Vs Filgrastim-Mobilised Peripheral Blood Progenitor Cell Transplantation In Patients With Early Leukaemia: First Results Of A Randomised Multicentre Trial Of The European Group For Blood And Marrow Transplantation. *Bone Marrow Transplantation*, *21*(10), Pp.995-1003.

40. Cesaro, S., Marson, P., Gazzola, M.V., De Silvestro, G., Destro, R., Pillon, M., Calore, E., Messina, C. And Zanesco, L., 2002. The Use Of Cytokine-Stimulated Healthy Donors In Allogeneic Stem Cell Transplantation. *Haematologica*, *87*(8 Suppl), Pp.35-41.
41. Becker, P.S., Wagle, M., Matous, S., Swanson, R.S., Pihan, G., Lowry, P.A., Stewart, F.M. And Heard, S.O., 1997. Spontaneous Splenic Rupture Following Administration Of Granulocyte Colony-Stimulating Factor (G-CSF): Occurrence In An Allogeneic Donor Of Peripheral Blood Stem Cells. *Biology Of Blood And Marrow Transplantation: Journal Of The American Society For Blood And Marrow Transplantation*, *3*(1), Pp.45-49.
42. Hatzimichael, E., Benetatos, L., Stebbing, J., Kapsali, E., Panayiotopoulou, S. And Bourantas, K.L., 2006. Spontaneous Splenic Haematoma In A Multiple Myeloma Patient Receiving Pegfilgrastim Support. *Clinical & Laboratory Haematology*, *28*(6), Pp.416-418.
43. Masood, N., Shaikh, A.J., Memon, W.A. And Idress, R., 2008. Splenic Rupture, Secondary To G-CSF Use For Chemotherapy Induced Neutropenia: A Case Report And Review Of Literature. *Cases Journal*, *1*(1), Pp.1-3.
44. Nuamah, N.M., Goker, H., Kilic, Y.A., Dagmoura, H. And Cakmak, A., 2006. Spontaneous Splenic Rupture In A Healthy Allogeneic Donor Of Peripheral-Blood Stem Cell Following The Administration Of Granulocyte Colony-Stimulating Factor (G-Csf). A Case Report And Review Of The Literature. *Haematologica*, *91*(5_Suppl), Pp.ECR08-ECR08.
45. Lee, S.J., Vogelsang, G. And Flowers, M.E., 2003. Chronic Graft-Versus-Host Disease. *Biology Of Blood And Marrow Transplantation*, *9*(4), Pp.215-233.
46. Przepiorka, D., Anderlini, P., Saliba, R., Cleary, K., Mehra, R., Khouri, I., Huh, Y.O., Giralt, S., Braunschweig, I., Van Besien, K. And Champlin, R., 2001. Chronic Graft-Versus-Host Disease After Allogeneic Blood Stem Cell Transplantation. *Blood, The Journal Of The American Society Of Hematology*, *98*(6), Pp.1695-1700.
47. Bradley, M.B. And Cairo, M.S., 2005. Cord Blood Immunology And Stem Cell Transplantation. *Human Immunology*, *66*(5), Pp.431-446.
48. Wang, J.C., Doedens, M. And Dick, J.E., 1997. Primitive Human Hematopoietic Cells Are Enriched In Cord Blood Compared With Adult Bone Marrow Or Mobilized Peripheral Blood As Measured By The Quantitative In Vivo SCID-Repopulating Cell Assay. *Blood, The Journal Of The American Society Of Hematology*, *89*(11), Pp.3919-3924.
49. Hogan, C.J., Shpall, E.J., Mcnulty, O., Mcniece, I., Dick, J.E., Shultz, L.D. And Keller, G., 1997. Engraftment And Development Of Human CD34+-Enriched Cells From Umbilical Cord Blood In NOD/Ltsz-Scid/Scid Mice. *Blood, The Journal Of The American Society Of Hematology*, *90*(1), Pp.85-96.
50. Grewal, S.S., Barker, J.N., Davies, S.M. And Wagner, J.E., 2003. Unrelated Donor Hematopoietic Cell Transplantation: Marrow Or Umbilical Cord Blood?. *Blood*, *101*(11), Pp.4233-4244.
51. Delaney, C., Heimfeld, S., Brashem-Stein, C., Voorhies, H., Manger, R.L. And Bernstein, I.D., 2010. Notch-Mediated Expansion Of Human Cord Blood Progenitor Cells Capable Of Rapid Myeloid Reconstitution. *Nature Medicine*, *16*(2), Pp.232-236.
52. Wang, J., Zhan, P., Ouyang, J., Chen, B., Zhou, R. And Yang, Y., 2010. Unrelated Donor Umbilical Cord Blood Transplantation Versus Unrelated Donor Bone Marrow Transplantation In Adult And Pediatric Patients: A Meta-Analysis. *Leukemia Research*, *34*(8), Pp.1018-1022.
53. Gribben, J.G., Zahrieh, D., Stephans, K., Bartlett-Pandite, L., Alyea, E.P., Fisher, D.C., Freedman, A.S., Mauch, P., Schlossman, R., Sequist, L.V. And Soiffer, R.J., 2005. Autologous And Allogeneic Stem Cell Transplantations For Poor-Risk Chronic Lymphocytic Leukemia. *Blood*, *106*(13), Pp.4389-4396.
54. Michallet, M., Archimbaud, E., Bandini, G., Rowlings, P.A., Deeg, H.J., Gahrton, G., Montserrat, E., Rozman, C., Gratwohl, A., Gale, R.P. And For The European Group For Blood And Marrow Transplantation And The International Bone Marrow Transplant Registry, 1996. HLA-Identical Sibling Bone Marrow Transplantation In Younger Patients With Chronic Lymphocytic Leukemia. *Annals Of Internal Medicine*, *124*(3), Pp.311-315.
55. Lim, Z., Brand, R., Martino, R., Van Biezen, A., Finke, J., Bacigalupo, A., Beelen, D., Devergie, A., Alessandrino, E., Willemze, R. And Ruutu, T., 2010. Allogeneic Hematopoietic Stem-Cell Transplantation For Patients 50 Years Or Older With Myelodysplastic Syndromes Or Secondary Acute Myeloid Leukemia. *Journal Of Clinical Oncology*, *28*(3), Pp.405-411.
56. Hsieh, M.Y., Chiou, T.J., Hung, G.Y. And Yen, H.J., 2010. Outcomes Of Matched Sibling And Alternative Donor Stem Cell Transplantation For 26 Children With Severe Aplastic Anemia. *International Journal Of Hematology*, *91*(1), Pp.54-60.
57. Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. And Storer, B., 2005. Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index: A New Tool For Risk Assessment Before Allogeneic HCT. *Blood*, *106*(8), Pp.2912-2919.
58. Sorror, M.L., Storer, B.E., Maloney, D.G., Sandmaier, B.M., Martin, P.J. And Storb, R., 2008. Outcomes After Allogeneic Hematopoietic Cell Transplantation With

Nonmyeloablative Or Myeloablative Conditioning Regimens For Treatment Of Lymphoma And Chronic Lymphocytic Leukemia. *Blood, The Journal Of The American Society Of Hematology*, *111*(1), Pp.446-452.

59. Farina, L., Bruno, B., Patriarca, F., Spina, F., Sorasio, R., Morelli, M., Fanin, R., Boccadoro, M. And Corradini, P., 2009. The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Clinical Outcomes In Lymphoma And Myeloma Patients After Reduced-Intensity Or Non-Myeloablative Allogeneic Stem Cell Transplantation. *Leukemia*, *23*(6), Pp.1131-1138.
60. Majhail, N.S., Brunstein, C.G., Mcavoy, S., Defor, T.E., Al-Hazzouri, A., Setubal, D., Arora, M., Le, C.T., Wagner, J.E. And Weisdorf, D.J., 2008. Does The Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study In A Large Cohort Of Umbilical Cord Blood And Matched Related Donor Transplants. *Biology Of Blood And Marrow Transplantation*, *14*(9), Pp.985-992.
61. Afessa, B. And Peters, S.G., 2006, June. Major Complications Following Hematopoietic Stem Cell Transplantation. In *Seminars In Respiratory And Critical Care Medicine* (Vol. 27, No. 03, Pp. 297-309). Copyright© 2006 By Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA..
62. Hatzimichael, E. And Tuthill, M., 2010. Hematopoietic Stem Cell Transplantation. *Stem Cells And Cloning: Advances And Applications*, *3*, P.105.
63. Goodrich, J.M., Reed, E.C., Mori, M., Fisher, L.D., Skerrett, S., Dandliker, P.S., Klis, B., Counts, G.W. And Meyers, J.D., 1991. Clinical Features And Analysis Of Risk Factors For Invasive Candidal Infection After Marrow Transplantation. *Journal Of Infectious Diseases*, *164*(4), Pp.731-740.
64. Boeckh, M., Leisenring, W., Riddell, S.R., Bowden, R.A., Huang, M.L., Myerson, D., Stevens-Ayers, T., Flowers, M.E., Cunningham, T. And Corey, L., 2003. Late Cytomegalovirus Disease And Mortality In Recipients Of Allogeneic Hematopoietic Stem Cell Transplants: Importance Of Viral Load And T-Cell Immunity. *Blood, The Journal Of The American Society Of Hematology*, *101*(2), Pp.407-414.
65. Andrei, G., De Clercq, E. And Snoeck, R., 2008. Novel Inhibitors Of Human CMV. *Current Opinion In Investigational Drugs (London, England: 2000)*, *9*(2), Pp.132-145.
66. Li, C.R., Greenberg, P.D., Gilbert, M.J., Goodrich, J.M. And Riddell, S.R., 1994. Recovery Of HLA-Restricted Cytomegalovirus (CMV)-Specific T-Cell Responses After Allogeneic Bone Marrow Transplant: Correlation With CMV Disease And Effect Of Ganciclovir Prophylaxis.
67. Schmidt-Hieber, M., Schwarck, S., Stroux, A., Thiel, E., Ganepola, S., Uharek, L. And Blau, I.W., 2009. Prophylactic Iv Igs In Patients With A High Risk For CMV After Allo-SCT. *Bone Marrow Transplantation*, *44*(3), Pp.185-192.
68. Hatzimichael, E. And Tuthill, M., 2010. Hematopoietic Stem Cell Transplantation. *Stem Cells And Cloning: Advances And Applications*, *3*, P.105.
69. Paston, S.J., Dodi, I.A. And Madrigal, J.A., 2004. Progress Made Towards The Development Of A CMV Peptide Vaccine. *Human Immunology*, *65*(5), Pp.544-549.
70. Pass, R.F., Zhang, C., Evans, A., Simpson, T., Andrews, W., Huang, M.L., Corey, L., Hill, J., Davis, E., Flanigan, C. And Cloud, G., 2009. Vaccine Prevention Of Maternal Cytomegalovirus Infection. *New England Journal Of Medicine*, *360*(12), Pp.1191-1199.
71. Couriel, D., Carpenter, P.A., Cutler, C., Bolaños-Meade, J., Treister, N.S., Gea-Banacloche, J., Shaughnessy, P., Hymes, S., Kim, S., Wayne, A.S. And Chien, J.W., 2006. Ancillary Therapy And Supportive Care Of Chronic Graft-Versus-Host Disease: National Institutes Of Health Consensus Development Project On Criteria For Clinical Trials In Chronic Graft-Versus-Host Disease: V. Ancillary Therapy And Supportive Care Working Group Report. *Biology Of Blood And Marrow Transplantation*, *12*(4), Pp.375-396.
72. Carlens, S., Ringden, O., Remberger, M., Lönnqvist, B., Hägglund, H., Klaesson, S., Mattsson, J., Svahn, B.M., Winiarski, J., Ljungman, P. And Aschan, J., 1998. Risk Factors For Chronic Graft-Versus-Host Disease After Bone Marrow Transplantation: A Retrospective Single Centre Analysis. *Bone Marrow Transplantation*, *22*(8), Pp.755-761.
73. Hahn, T., Mccarthy Jr, P.L., Zhang, M.J., Wang, D., Arora, M., Frangoul, H., Gale, R.P., Hale, G.A., Horan, J., Isola, L. And Maziarz, R.T., 2008. Risk Factors For Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants For Adults With Leukemia. *Journal Of Clinical Oncology*, *26*(35), P.5728.
74. Remberger, M., Persson, U., Hauzenberger, D. And Ringdén, O., 2002. An Association Between Human Leucocyte Antigen Alleles And Acute And Chronic Graft-Versus-Host Disease After Allogeneic Haematopoietic Stem Cell Transplantation. *British Journal Of Haematology*, *119*(3), Pp.751-759.
75. Couriel, D., Caldera, H., Champlin, R. And Komanduri, K., 2004. Acute Graft-Versus-Host Disease: Pathophysiology, Clinical Manifestations, And Management. *Cancer*, *101*(9), Pp.1936-1946.
76. Firoz, B.F., Lee, S.J., Nghiem, P. And Qureshi, A.A., 2006. Role Of Skin Biopsy To Confirm Suspected Acute Graft-Vs-Host Disease: Results Of Decision Analysis. *Archives Of Dermatology*, *142*(2), Pp.175-182.
77. GLUCKSBERG, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K.G. And Thomas, E.D., 1974. Clinical Manifestations Of Graft-Versus-Host Disease In Human Recipients Of Marrow From Hl-A-Matched Sibling Donor, S. *Transplantation*, *18*(4), Pp.295-304.

78. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. And Thomas, E.D., 1995. 1994 Consensus Conference On Acute GVHD Grading. *Bone Marrow Transplantation*, *15*(6), Pp.825-828.
79. Rowlings, P.A., Przepiorka, D., Klein, J.P., Gale, R.P., Passweg, J.R., Jean Henslee-Downey, P., Cahn, J.Y., Calderwood, S., Gratwohl, A., Socié, G. And Abecasis, M.M., 1997. IBMTR Severity Index For Grading Acute Graft-Versus-Host Disease: Retrospective Comparison With Glucksberg Grade. *British Journal Of Haematology*, *97*(4), Pp.855-864.
80. Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Farewell, V. And Hansen, J., 1986. Methotrexate And Cyclosporine Compared With Cyclosporine Alone For Prophylaxis Of Acute Graft Versus Host Disease After Marrow Transplantation For Leukemia. *New England Journal Of Medicine*, *314*(12), Pp.729-735.
81. Greinix, H.T., Knobler, R.M., Worel, N., Schneider, B., Schneeberger, A., Hoecker, P., Mitterbauer, M., Rabitsch, W., Schulenburg, A. And Kalhs, P., 2006. The Effect Of Intensified Extracorporeal Photochemotherapy On Long-Term Survival In Patients With Severe Acute Graft-Versus-Host Disease. *Haematologica*, *91*(3), Pp.405-408.
82. Kim, S.S., 2007. Treatment Options In Steroid-Refractory Acute Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation. *Annals Of Pharmacotherapy*, *41*(9), Pp.1436-1444.
83. Atkinson, K., Horowitz, M.M., Gale, R.P., Van Bekkum, D.W., Gluckman, E., Good, R.A., Jacobsen, N., Kolb, H.J., Rimm, A.A. And Ringden, O., 1990. Risk Factors For Chronic Graft-Versus-Host Disease After HLA-Identical Sibling Bone Marrow Transplantation.
84. Sullivan, K.M., Shulman, H.M., Storb, R., Weiden, P.L., Witherspoon, R.P., Mcdonald, G.B., Schubert, M.M., Atkinson, K. And Thomas, E.D., 1981. Chronic Graft-Versus-Host Disease In 52 Patients: Adverse Natural Course And Successful Treatment With Combination Immunosuppression.
85. Sullivan, K.M., 1986. Acute And Chronic Graft-Versus-Host Disease In Man. *The International Journal Of Cell Cloning*, *4*(S1), Pp.42-93.
86. Häusermann, P., Walter, R.B., Halter, J., Biedermann, B.C., Tichelli, A., Itin, P. And Gratwohl, A., 2008. Cutaneous Graft-Versus-Host Disease: A Guide For The Dermatologist. *Dermatology*, *216*(4), Pp.287-304.
87. STORB, R., PRENTICE, R.L., SULLIVAN, K.M., SHULMAN, H.M., DEEG, H.J., DONEY, K.C., BUCKNER, C.D., CLIFT, R.A., WITHERSPOON, R.P., APPELBAUM, F.A. And SANDERS, J.E., 1983. Predictive Factors In Chronic Graft-Versus-Host Disease In Patients With Aplastic Anemia Treated By Marrow Transplantation From HLA-Identical Siblings. *Annals Of Internal Medicine*, *98*(4), Pp.461-466.
88. Sullivan, K.M., Witherspoon, R.P., Storb, R., Deeg, H.J., Dahlberg, S., Sanders, J.E., Appelbaum, F.R., Doney, K.C., Weiden, P., Anasetti, C. And Loughran, T.P., 1988. Alternating-Day Cyclosporine And Prednisone For Treatment Of High-Risk Chronic Graft-V-Host Disease. *Blood*, *72*(2), Pp.555-561.
89. Vogelsang, G.B., 2001. How I Treat Chronic Graft-Versus-Host Disease. *Blood, The Journal Of The American Society Of Hematology*, *97*(5), Pp.1196-1201.
90. Cutler, C., Miklos, D., Kim, H.T., Treister, N., Woo, S.B., Bienfang, D., Klickstein, L.B., Levin, J., Miller, K., Reynolds, C. And Macdonell, R., 2006. Rituximab For Steroid-Refractory Chronic Graft-Versus-Host Disease. *Blood*, *108*(2), Pp.756-762.
91. Weisdorf, D.J., Nelson, G., Lee, S.J., Haagenson, M., Spellman, S., Antin, J.H., Bolwell, B., Cahn, J.Y., Cervantes, F., Copelan, E. And Gale, R., 2009. Sibling Versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation For Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-Versus-Host Disease But Not Less Relapse. *Biology Of Blood And Marrow Transplantation*, *15*(11), Pp.1475-1478.
92. Saarinen-Pihkala, U.M., Gustafsson, G., Ringdén, O., Heilmann, C., Glomstein, A., LöNnerholm, G., Abrahamsson, J., Bekassy, A.N., Schroeder, H., Mellander, L. And Nordic Society Of Pediatric Hematology And Oncology, 2001. No Disadvantage In Outcome Of Using Matched Unrelated Donors As Compared With Matched Sibling Donors For Bone Marrow Transplantation In Children With Acute Lymphoblastic Leukemia In Second Remission. *Journal Of Clinical Oncology*, *19*(14), Pp.3406-3414.
93. Chiodi, S., Spinelli, S., Ravera, G., Petti, A.R., Van Lint, M.T., Lamparelli, T., Gualandi, F., Occhini, D., Mordini, N., Berisso, G. And Bregante, S., 2000. Quality Of Life In 244 Recipients Of Allogeneic Bone Marrow Transplantation. *British Journal Of Haematology*, *110*(3), Pp.614-619.
94. Heinonen, H., Volin, L., Uutela, A., Zevon, M., Barrick, C. And Ruutu, T., 2001. Quality Of Life And Factors Related To Perceived Satisfaction With Quality Of Life After Allogeneic Bone Marrow Transplantation. *Annals Of Hematology*, *80*(3), Pp.137-143.
95. Kiss, T.L., Abdolell, M., Jamal, N., Minden, M.D., Lipton, J.H. And Messner, H., 2002. Long-Term Medical Outcomes And Quality-Of-Life Assessment Of Patients With Chronic Myeloid Leukemia Followed At Least 10 Years After Allogeneic Bone Marrow Transplantation. *Journal Of Clinical Oncology*, *20*(9), Pp.2334-2343.
96. Andrykowski, M.A., Greiner, C.B., Altmaier, E.M., Burish, T.G., Antin, J.H., Gingrich, R., Mcgarigle, C. And Henslee-Downey, P., 1995. Quality Of Life Following Bone Marrow Transplantation: Findings From A Multicentre Study. *British Journal Of Cancer*, *71*(6), Pp.1322-1329.

97. Baker, F., Wingard, J.R., Curbow, B., Zabora, J., Jodrey, D., Fogarty, L. And Legro, M., 1994. Quality Of Life Of Bone Marrow Transplant Long-Term Survivors. *Bone Marrow Transplantation*, *13*(5), Pp.589-596.
98. Fraser, C.J., Bhatia, S., Ness, K., Carter, A., Francisco, L., Arora, M., Parker, P., Forman, S., Weisdorf, D., Gurney, J.G. And Baker, K.S., 2006. Impact Of Chronic Graft-Versus-Host Disease On The Health Status Of Hematopoietic Cell Transplantation Survivors: A Report From The Bone Marrow Transplant Survivor Study. *Blood*, *108*(8), Pp.2867-2873.
99. Lee, S.J., Fairclough, D., Parsons, S.K., Soiffer, R.J., Fisher, D.C., Schlossman, R.L., Antin, J.H. And Weeks, J.C., 2001. Recovery After Stem-Cell Transplantation For Hematologic Diseases. *Journal Of Clinical Oncology*, *19*(1), Pp.242-252.
100. Harder, H., Van Gool, A.R., Cornelissen, J.J., Duivenvoorden, H.J., Eijkenboom, W.M., Barge, R.M. And Van Den Bent, M.J., 2005. Assessment Of Pre-Treatment Cognitive Performance In Adult Bone Marrow Or Haematopoietic Stem Cell Transplantation Patients: A Comparative Study. *European Journal Of Cancer*, *41*(7), Pp.1007-1016.